Alivus Life Sciences Ltd

Thu 27/08/2026,15:53:49 | NSE : ALIVUS

₹1358.20-2.60 (-0.19%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 1362.90

Previous Close

₹ 1360.80

Volume

60525

Mkt Cap ( ₹ Cr)

₹ 16674.82

High

₹ 1400.00

Low

₹ 1353.10

52 Week High

₹ 1418.00

52 Week Low

₹ 819.00

Book Value Per Share

₹ 284.45

Dividend Yield

0.00

Face Value

₹ 2.00

What's Your Call?

Collective community sentiment on Alivus Life Sciences Ltd

Your Vote -

Buy

90.78%

Hold

7.28%

Sell

1.94%

90.78%

206 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

NaN%

Sell Order Quantity

NaN%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Alivus Life Sciences Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    25 Aug 2026, 2:34PM Alivus Life Sciences Limited has informed the Exchange about Schedule of Investor/Analyst meeting

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    25 Aug 2026, 2:28PM Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meetings

  • Alivus Life Sciences has declared 250% Final dividend for the financial year March 2026

    19 Aug 2026, 2:40PM Alivus Life Sciences Ltd. on Thursday, 14 May 2026, has announced Final dividend of 250 percent on Equity Share, to its shareholders holding shares on

  • Alivus Life Sciences - Press Release

    18 Aug 2026, 5:36PM Alivus Life Sciences Limited has informed the Exchange regarding a press release dated August 18, 2026, titled ""Alivus Life Sciences announces acquis

  • Alivus Life Sciences - Outcome of Board Meeting

    18 Aug 2026, 5:29PM Enclosed please find herewith intimation pursuant to Regulation 30 of SEBI (LODR), 2015 with respect to acquisition.

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    18 Aug 2026, 5:33PM Enclosed please find herewith Press Release with respect to Acquisition.

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Acquisition

    18 Aug 2026, 5:24PM Enclosed please find herewith intimation pursuant to Regulation 30 of SEBI (LODR), 2015 with respect to acquisition.

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    13 Aug 2026, 11:59AM Alivus Life Sciences Limited has informed the Exchange about Schedule of meet of Investor/Analyst.

  • Alivus Life Sciences - Copy of Newspaper Publication

    13 Aug 2026, 11:53AM Alivus Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication of Notice of 15th Annual General Meeting and e-voting infor

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    13 Aug 2026, 11:57AM Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting

  • Alivus Life Sciences - Updates

    11 Aug 2026, 6:08PM Alivus Life Sciences Limited has informed the Exchange regarding 'Business Responsibility & Sustainability Report for FY 2025-26'.

  • Alivus Life Sciences - Business Responsibility and Sustainability Reporting (BRSR)

    11 Aug 2026, 6:05PM Please find enclosed herewith the Business Responsibility & Sustainability Report for FY 2025-26

  • Alivus Life Sciences - Shareholders meeting

    11 Aug 2026, 5:48PM Alivus Life Sciences Limited has informed the Exchange regarding Notice of Annual General Meeting (AGM) to be held on September 8, 2026. Enclosed plea

  • Alivus Life Sciences - Reg. 34 (1) Annual Report.

    11 Aug 2026, 5:54PM Please find enclosed herewith Integrated Annual Report FY 2025-26 under Regulation 34 (1) of the SEBI (Listing Obligations and Disclosure Requirements

  • Alivus Life Sciences - Notice Of 15Th Annual General Meeting Of The Company For FY 2025-26 As Required Under Regulation 30 Of

    11 Aug 2026, 5:46PM Please find attached herewith Notice convening the 15th Annual General Meeting.

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    7 Aug 2026, 10:16PM Alivus Life Sciences Limited has informed the Exchange about Schedule of meet

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    7 Aug 2026, 12:29PM Please find attached herewith details of Analyst/Investor meet.

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    7 Aug 2026, 12:26PM Please find attached herewith transcript of Earnings call held on 31 July, 2026.

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    7 Aug 2026, 12:20PM Alivus Life Sciences Limited has informed the Exchange about Schedule of meet

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    7 Aug 2026, 12:17PM Alivus Life Sciences Limited has informed the Exchange about Transcript of earnings call held on July 31, 2026.

  • Alivus Life Sciences - Copy of Newspaper Publication

    6 Aug 2026, 6:21PM Alivus Life Sciences Limited has informed the Exchange about Copy of Newspaper Publication regarding intimation of 15th AGM.

  • Alivus Life Sciences - Record Date

    6 Aug 2026, 3:13PM Alivus Life Sciences Limited has informed the Exchange that Record date for the purpose of Dividend is 01-Sep-2026.

  • Alivus Life Sciences - Shareholders meeting

    6 Aug 2026, 3:11PM Alivus Life Sciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 08, 2026

  • Alivus Life Sciences - Intimation Of Record Date For Dividend

    6 Aug 2026, 3:02PM Intimation of Record date for Dividend.

  • Alivus Life Sciences - Intimation Of 15Th Annual General Meeting And Record Date.

    6 Aug 2026, 2:57PM Intimation of 15th Annual General Meeting and Record date.

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    31 Jul 2026, 11:58AM Alivus Life Sciences Limited has informed the Exchange about Link of Recording

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    31 Jul 2026, 11:45AM We hereby confirm that we have uploaded audio recording of the Q1 FY2027 Earnings Call held on July 31, 2026 on the website of the Company.\r\n

  • Alivus Life Sciences - Updates

    30 Jul 2026, 7:32PM Alivus Life Sciences Limited has informed the Exchange regarding 'Allotment of Equity Shares under ""Employee Stock Option Scheme, 2021""'.

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

    30 Jul 2026, 7:11PM Enclosed please find herewith intimation with respect to allotment of equity shares under 'Employee Stock Options Scheme, 2021'

  • Alivus Life Sciences - Investor Presentation

    30 Jul 2026, 7:04PM Alivus Life Sciences Limited has informed the Exchange about Investor Presentation

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Investor Presentation

    30 Jul 2026, 7:04PM Enclosed please find herewith Investors Presentation for Q1 FY 2026-27.

  • Alivus Life Sciences - Press Release

    30 Jul 2026, 7:01PM Alivus Life Sciences Limited has informed the Exchange regarding a press release dated July 30, 2026, titled ""Press Release of the Company for the Fi

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    30 Jul 2026, 6:58PM Enclosed please find herewith Press Release of the Company for the first quarter ended June 30, 2026.

  • Alivus Life Sciences - Unaudited Financial Results For The First Quarter Ended June 30, 2026.

    30 Jul 2026, 6:51PM Enclosed please find herewith unaudited financial results for the first quarter ended June 30, 2026.

  • Alivus Life Sciences - Outcome of Board Meeting

    30 Jul 2026, 6:43PM Alivus Life Sciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.

  • Alivus Life Sciences - Board Meeting Outcome for Unaudited Financial Results For The First Quarter Ended June 30, 2026

    30 Jul 2026, 6:43PM Enclosed please find herewith unaudited financial results for the first quarter ended June 30, 2026.

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    23 Jul 2026, 4:21PM Alivus Life Sciences Limited has informed the Exchange about Schedule of meet - Earnings Call

  • Alivus Life Sciences - Trading Window

    23 Jul 2026, 2:36PM Alivus Life Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulati

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    23 Jul 2026, 4:27PM Enclosed please find herewith the details of Earnings Call slated for Friday, July 31, 2026 from 8:30 a.m. to 9:30 a.m. (IST), for your information an

  • Alivus Life Sciences - Board Meeting Intimation for Considering And Approving Unaudited Financial Results Of The Company For

    23 Jul 2026, 2:21PM Alivus Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2026 ,inter alia, to consider

  • Alivus Life Sciences has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026

    13 Jul 2026, 7:00PM As of June 2026, 74.87% is owned by Indian Promoters and 25.13% by Public. <p align=justify> Institutional holds 12.72% (Insurance Companies 0.27%) an

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    23 Jun 2026, 6:16PM Alivus Life Sciences Limited has informed the Exchange about Schedule of meet

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    23 Jun 2026, 6:12PM Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Institutional Investor Meeti

  • Alivus Life Sciences - Disclosure under SEBI Takeover Regulations

    12 Jun 2026, 7:25PM Nirma Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acq

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    10 Jun 2026, 6:06PM Alivus Life Sciences Limited has informed the Exchange about Schedule of Analyst/ Institutional Investor meeting.

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    10 Jun 2026, 6:01PM Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Analyst / Institutional Inve

  • Alivus Life Sciences - Analysts/Institutional Investor Meet/Con. Call Updates

    4 Jun 2026, 5:04PM Alivus Life Sciences Limited has informed the Exchange about Schedule of meet

  • Alivus Life Sciences - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    4 Jun 2026, 5:03PM Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting

  • Glenmark Life Science

    11 Jul 2024 , 10:12AM Glenmark Pharmaceuticals' board of directors approved the sale of a 7.84% stake or 96,09,571 equity shares, in Glenmark Life Sciences Limited, as stated in its filing to the exchanges on Wednesday. The stake sale will be done through the stock exchanges via an offer for sale. (Negative)

  • Glenmark Life signs master supply agreement with a Japanese innovator pharma co

    19 Jan 2024 , 11:07AM Glenmark Life Sciences signs Master Supply Agreement with a leading Japanese Innovator pharmaceutical Company

  • Glenmark Lifesciences

    31 Jul 2023 , 10:32AM The Nirma Group has emerged as the frontrunner to acquire Glenmark Life Sciences (GLS), an 82.84% subsidiary of Glenmark Pharmaceuticals. Strong positive for Glenmark Lifesciences

  • Glenmark Life Sciences report strong Q1 earnings

    21 Jul 2023 , 1:38PM Glenmark Life Sciences reported an 18% y-o-y rise in revenue to Rs 578.45 Cr in Q1FY24. It was driven by a 13.3% y-o-y increase in Generic API revenue to Rs. 504.2 Cr due to strong growth in regulated markets and steady growth in emerging markets while CDMO business recorded 91.0% growth y-o-y to Rs. 46.4 Cr due to healthy recovery in demand. As gross margins improved 385 bps y-o-y to 57% the gross profits increased 27% y-o-y to Rs. 330.41 Cr. This was driven by lower input costs and improved products mix. As a result, EBITDA increased 32% y-o-y to Rs. 193.16 Cr. while EBITDA margins remained stable y-o-y at 33% in Q1FY24. However, with 193% y-o-y rise in finance costs to Rs. 0.40 Cr the PAT increased at a slower but strong pace of 25% y-o-y to Rs. 135.45 Cr in Q1FY24. However, on a q-o-q basis, revenue and PAT declined at 7% each. Sales declined q-o-q due to high base effect. The management is hopeful of growth in the coming quarters on the back of capacity expansion and product pipeline as well as improved demand environment and supply situation. Positive for the stock.
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Alivus Life Sciences Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 3332.132 2817.372 2332.322 2138.207 2054.312
Liabilities 3332.132 2817.372 2332.322 2138.207 2054.312
Equity 24.547 24.507 24.505 24.505 24.505
Gross Profit 797.284 682.584 674.246 642.293 616.06
Net Profit 564.483 485.627 470.888 466.961 418.724
Cash From Operating Activities 565.413 391.524 413.515 313.404 597.585
NPM(%) 22.12 20.34 20.62 21.6 19.72
Revenue 2551.832 2386.884 2283.214 2161.22 2123.214
Expenses 1754.548 1704.3 1608.968 1518.927 1507.154
ROE(%) 16.16 13.9 13.48 13.37 11.99

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
01 Sep 2026 5 250 0 1064.1
01 Sep 2025 5 250 0 1206
17 Oct 2023 22.5 1125 0 617.7
24 Mar 2023 21 1050 0 375.3
15 Sep 2022 10.5 525 0 489
22 Nov 2021 10.5 525 0 632.7

Peers

Other companies within the same industry or sector that are comparable to Alivus Life Sciences Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 890.25 2.36 22.52 777.38 -26.19 0.56
Lotus Eye Hospital and Institute Ltd 112.63 0.91 1609.00 2832.66 0.39 0.00
Vaishali Pharma Ltd 8.33 1.96 26.03 17770.24 15.42 0.00
Astec Lifesciences Ltd 585.90 -1.28 0.00 3035.05 -363.14 0.00

Company Info

The Company was incorporated as `Zorg Laboratories Private Limited', a private limited company under the Companies Act, 1956 on June 23, 2011 at Pune and was granted the certificate of incorporation by the RoC. the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated July 4, 2018. For further details, please see - "Details regarding material acquisitions or divestments of business/ undertakings, mergers, amalgamations or any revaluation of assets, in the last 10 years - Acquisition by Glenmark Pharmaceuticals Limited" on page 151. Pursuant to the acquisition, the name of the Company was changed to `Glenmark Life Sciences Private Limited' by way of a special resolution passed by the shareholders of the Company on July 25, 2018 and a fresh certificate of incorporation dated August 10, 2018 was issued by the RoC. A shareholders' resolution was passed on August 13, 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated August 28, 2018 was issued by the RoC. Thereafter, the business of active pharmaceutical ingredients was acquired by the Company from the Promoter pursuant to the Business Purchase Agreement.Major events and milestones of the Company :2002- The Promoter established its API business- Established manufacturing plant at Kurkumbh, Maharashtra2003- First product registered with US-FDA- Acquired GlaxoSmithKline's (GSK) API manufacturing plant in Ankleshwar, Gujarat2004- Commenced manufacturing at Mohol, Maharashtra2008- Ankleshwar plant at Gujarat inspected by US-FDA2012- Ankleshwar plant inspected by PMDA and AFSSAPS2013- Commenced manufacturing at Dahej, Gujarat- Ankleshwar plant inspected by COFEPRIS2015- Dahej plant inspected by US-FDA2016- Dahej plant inspected by PMDA Japan2018- Dahej plant inspected by EDQM, ANSM and US-FDA- Mohol plant inspected by US-FDA2019- The API business was spun off into the Company- Ankleshwar plant inspected by US-FDA, Health Canada and PMDA, Japan2021- Achieved milestone of 403 cumulative drug master files (DMF) registrations across multiple markets globally 2023 -The Company had announced that its board had given the green light to divest a 75% stake in its subsidiary GLS to Nirma Ltd for a total of Rs 5,651.5 crore. 2025 -The Company name has changed from Glenmark Life Sciences Ltd to Alivus Life Sciences Ltd. -The Company Informed regarding Agreement and Power Supply Agreement between Alivus Life Sciences Ltd. and Torrent Urja 19 Private Ltd.

The Company was incorporated as `Zorg Laboratories Private Limited', a private limited company under the Companies Act, 1956 on June 23, 2011 at Pune and was granted the certificate of incorporation by the RoC. the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated July 4, 2018. For further details, please see - "Details regarding material acquisitions or divestments of business/ undertakings, mergers, amalgamations or any revaluation of assets, in the last 10 years - Acquisition by Glenmark Pharmaceuticals Limited" on page 151. Pursuant to the acquisition, the name of the Company was changed to `Glenmark Life Sciences Private Limited' by way of a special resolution passed by the shareholders of the Company on July 25, 2018 and a fresh certificate of incorporation dated August 10, 2018 was issued by the RoC. A shareholders' resolution was passed on August 13, 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated August 28, 2018 was issued by the RoC. Thereafter, the business of active pharmaceutical ingredients was acquired by the Company from the Promoter pursuant to the Business Purchase Agreement.Major events and milestones of the Company :2002- The Promoter established its API business- Established manufacturing plant at Kurkumbh, Maharashtra2003- First product registered with US-FDA- Acquired GlaxoSmithKline's (GSK) API manufacturing plant in Ankleshwar, Gujarat2004- Commenced manufacturing at Mohol, Maharashtra2008- Ankleshwar plant at Gujarat inspected by US-FDA2012- Ankleshwar plant inspected by PMDA and AFSSAPS2013- Commenced manufacturing at Dahej, Gujarat- Ankleshwar plant inspected by COFEPRIS2015- Dahej plant inspected by US-FDA2016- Dahej plant inspected by PMDA Japan2018- Dahej plant inspected by EDQM, ANSM and US-FDA- Mohol plant inspected by US-FDA2019- The API business was spun off into the Company- Ankleshwar plant inspected by US-FDA, Health Canada and PMDA, Japan2021- Achieved milestone of 403 cumulative drug master files (DMF) registrations across multiple markets globally 2023 -The Company had announced that its board had given the green light to divest a 75% stake in its subsidiary GLS to Nirma Ltd for a total of Rs 5,651.5 crore. 2025 -The Company name has changed from Glenmark Life Sciences Ltd to Alivus Life Sciences Ltd. -The Company Informed regarding Agreement and Power Supply Agreement between Alivus Life Sciences Ltd. and Torrent Urja 19 Private Ltd.

Parent Organisation

Alivus Life Sciences Ltd.

Founded

23/06/2011

Managing Director

Dr.Yasir Rawjee

NSE Symbol

ALIVUSEQ

FAQ